- Home
- BRBI vs LRMR Comparison
BRBI vs LRMR Comparison
Compare BRBI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRBI | LRMR |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Brazil | United States |
| Employees | 188 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.0M | 455.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BRBI | LRMR |
|---|---|---|
| Price | $15.93 | $4.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 3.9K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.24 | $1,816.14 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.54 | $1.73 |
| 52 Week High | $67.01 | $6.42 |
Technical Indicators
Market Signals| Indicator | BRBI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 51.99 |
| Support Level | $13.77 | $3.14 |
| Resistance Level | $16.46 | $5.36 |
| Average True Range (ATR) | 0.29 | 0.26 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 78.80 | 43.68 |
Price Performance
Historical ComparisonAbout BRBI BRBI BR Partners S.A. ADSs
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.